Product Description
This novel fibrinolytic agent is a 136 amino acid single chain protein secreted by some strains of Staphylococcus aureus and readily produced by recombinant DNA technology. Two natural variants of recombinant staphylokinase, THR-100 and SakSTAR, have been developed for investigational use in preliminary trials.Ê (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01305226)
Mechanisms of Action: PLA Activator
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bharat Biotech International Limited
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Myocardial Infarction
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01305226 |
THR-100 | P3 |
Completed |
Myocardial Infarction |
2011-08-01 |
2019-03-19 |
Treatments |